1-[(4-溴苯基)甲基]-4-甲基哌嗪 | 368879-17-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[(4-溴苯基)甲基]-4-甲基哌嗪
• 中文别名: 1-(4-溴苯甲基)-4-甲基哌嗪；1-(4-溴苄基)-4-甲基哌嗪
• 英文名称: 1-(4-bromobenzyl)-4-methylpiperazine
• 英文别名: 1-[(4-bromophenyl)methyl]-4-methylpiperazine
• CAS: 368879-17-8
• 化学式: C₁₂H₁₇BrN₂
• mdl: MFCD00811183
• 分子量: 269.184
• InChiKey: CXAOXDKQUDHTBK-UHFFFAOYSA-N

物化性质

• 沸点：
  325.3±27.0 °C(Predicted)
• 密度：
  1.325±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090
• 储存条件：
  存放于惰性气体中，避免与空气接触。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-[(4-Bromophenyl)methyl]-4-methylpiperazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-[(4-Bromophenyl)methyl]-4-methylpiperazine
CAS number: 368879-17-8

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H17BrN2
Molecular weight: 269.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-[(4-溴苯基)甲基]-4-甲基哌嗪 在 正丁基锂 、 硼酸三异丙酯 作用下， 以 四氢呋喃 为溶剂， 以67.3%的产率得到4-((4-甲基哌嗪-1-基)甲基)苯硼酸
  参考文献：
  名称：

  [EN] PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS
  [FR] COMPOSÉS PEPTIDYLNITRILE EN TANT QU'INHIBITEURS DE LA DIPEPTIDYLE PEPTIDASE I

  摘要：

  该发明涉及式（I）化合物及其作为选择性二肽基肽酶I抑制剂的用途，以及包含该化合物的药物组合物，以及涉及该化合物的治疗方法。

  公开号：

  WO2015032943A1
• 作为产物：
  描述：

  对溴甲苯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 potassium carbonate 作用下， 以 四氯化碳 、 乙腈 为溶剂， 反应 5.0h， 生成 1-[(4-溴苯基)甲基]-4-甲基哌嗪
  参考文献：
  名称：

  基于结构的优化导致了NSC765844的发现，NSC765844是一种高效，毒性较小且口服有效的双重PI3K / mTOR抑制剂

  摘要：

  磷酸肌醇3-激酶（PI3K）家族是广泛的人类癌症中最常被激活的酶之一。因此，抑制PI3K代表了一种有前途的癌症治疗策略。在本文中，设计了一系列苄胺取代的芳基磺酰胺类化合物，并使用整合了重点文库设计和虚拟筛选的策略合成了PI3K / mTOR双重抑制剂，从而发现了13b（NSC765844）。化合物13b对PI3Kα，β，γ，δ和mTOR的IC 50分别具有1.3、1.8、1.5、3.8和3.8 nM的强酶抑制作用。通过体外细胞毒性筛选程序在NCI中进一步评估了13b。GI平均的广谱抗肿瘤活性发现针对大约60个人类肿瘤细胞系的50值为18.6nM。图13b显示了用于动物研究的有利的理化性质和优异的药代动力学特征。当在A549非小细胞肺癌异种移植和BEL7404人肝细胞癌异种移植模型中口服给药时，它可以显着抑制肿瘤的生长。基于其出色的体内功效和出色的药代动力学特征，13b已被选作有希望的抗癌药物候选物，用于进一步的临床前研究。

  DOI：

  10.1016/j.ejmech.2016.06.030

文献信息

• [EN] KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME<br/>[FR] INHIBITEURS DE KINASES ET PROCÉDÉ DE TRAITEMENT DU CANCER AVEC CEUX-CI
  申请人：UNIV HEALTH NETWORK

  公开号：WO2010115279A1

  公开（公告）日：2010-10-14

  The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

  这项发明涉及一种由以下结构式表示的化合物及其药用可接受的盐：由该结构式表示的化合物是激酶抑制剂，因此在此披露用于治疗癌症。结构式中变量的定义在此提供。
• New Pyridinones and Isoquinolinones as Inhibitors of the Bromodomain BRD9
  申请人：Boehringer Ingelheim International GmbH

  公开号：US20180044335A1

  公开（公告）日：2018-02-15

  The present invention encompasses compounds of general formula (I) wherein the groups R 1 to R 9 , X 1 and X 2 have the meanings given in the claims and in the specification. The compounds of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation, e.g. cancer, pharmaceutical preparations containing such compounds and their uses as a medicament.

  本发明涵盖了一般式（I）的化合物，其中基团R1至R9，X1和X2的含义如权利要求和说明书中所述。本发明的化合物适用于治疗由细胞过度或异常增殖所特征化的疾病，例如癌症，含有这种化合物的制药制剂以及它们作为药物的用途。
• Transnitrilation from Dimethylmalononitrile to Aryl Grignard and Lithium Reagents: A Practical Method for Aryl Nitrile Synthesis
  作者：Jonathan T. Reeves、Christian A. Malapit、Frederic G. Buono、Kanwar P. Sidhu、Maurice A. Marsini、C. Avery Sader、Keith R. Fandrick、Carl A. Busacca、Chris H. Senanayake

  DOI：10.1021/jacs.5b06136

  日期：2015.7.29

  An electrophilic cyanation of aryl Grignard or lithium reagents, generated in situ from the corresponding aryl bromides or iodides, by a transnitrilation with dimethylmalononitrile (DMMN) was developed. DMMN is a commercially available, bench-stable solid. The transnitrilation with DMMN avoids the use of toxic reagents and transition metals and occurs under mild reaction conditions, even for extremely

  开发了芳基格氏试剂或锂试剂的亲电氰化，由相应的芳基溴化物或碘化物原位生成，通过与二甲基丙二腈 (DMMN) 进行腈基转移。DMMN 是市售的、工作台稳定的固体。使用 DMMN 进行的腈基转移避免了使用有毒试剂和过渡金属，并且在温和的反应条件下发生，即使对于空间位阻非常大的底物也是如此。由定向邻位锂化产生的芳基锂物质的腈基转腈作用使净 CH 氰化成为可能。Thorpe 型亚胺加合物在反应中的中介作用是通过从淬灭反应中分离相应的酮来支持的。计算研究支持亚胺加合物逆向索普碎裂的能量有利性。
• 1, 2, 4-TRIAZOLONE DERIVATIVE
  申请人：Kuwada Takeshi

  公开号：US20130197217A1

  公开（公告）日：2013-08-01

  The present invention provides a 1,2,4-triazolone derivative represented by Formula (1A) having an antagonistic activity on the arginine-vasopressin 1b receptor or a pharmaceutically acceptable salt thereof and provides a pharmaceutical composition comprising the compound or the salt as an active ingredient, in particular, a therapeutic or preventive agent exhibiting favorable pharmacokinetics in a disease such as mood disorder, anxiety disorder, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal disease, drug addiction, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, head injury, inflammation, immune-related disease, or alopecia.

  本发明提供了一种1,2,4-三唑酮衍生物，其表示为式（1A），具有对精氨酸加压素1b受体的拮抗活性或其药用盐，并提供了包含该化合物或盐作为活性成分的药物组合物，特别是在诸如情绪障碍、焦虑障碍、精神分裂症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃肠疾病、药物成瘾、癫痫、脑梗死、脑缺血、脑水肿、头部损伤、炎症、免疫相关疾病或脱发等疾病中展现良好药代动力学的治疗或预防剂。
• [EN] PEPTIDYL NITRILCOMPOUNDS AS PEPTIDASE INHIBITORS<br/>[FR] COMPOSÉS DE PEPTIDYLNITRILE À TITRE D'INHIBITEURS DE PEPTIDASES
  申请人：PROZYMEX AS

  公开号：WO2012119941A1

  公开（公告）日：2012-09-13

  The invention relates to compounds of Formula (II) and their use in theraphy as peptidase inhibitors.

  该发明涉及公式（II）化合物及其在治疗中作为肽酶抑制剂的用途。